Estonia - estone - Ravimiamet

medana pharma s.a. - latanoprost - silmatilgad, lahus - 50mcg 1ml 2.5ml 3tk; 50mcg 1ml 2.5ml 1tk

Estonia - estone - Ravimiamet

unimed pharma spol. s r.o. - latanoprost - silmatilgad, lahus - 50mcg 1ml 2.5ml 1tk

Estonia - estone - Ravimiamet

ratiopharm gmbh - latanoprost - silmatilgad, lahus - 50mcg 1ml 2.5ml 1tk; 50mcg 1ml 2.5ml 6tk

Estonia - estone - Ravimiamet

bausch + lomb ireland limited - latanoprost - silmatilgad, lahus - 50mcg 1ml 2.5ml 1tk; 50mcg 1ml 2.5ml 3tk

Unione Europea - estone - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - ravimid hingamisteede obstruktiivsete haiguste, - allergiline asthmaxolair on näidustatud täiskasvanud, noorukid ja lapsed (6 kuni.

Estonia - estone - Ravimiamet

cipla europe nv - latanoprost - silmatilgad, lahus - 50mcg 1ml 2.5ml 1tk

Estonia - estone - Ravimiamet

mcneil healthcare (ireland) limited - ksülometasoliin+dekspantenool - ninasprei, lahus - 1mg+50mg 1ml 10ml 1tk

Unione Europea - estone - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorraagilised ained - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Estonia - estone - Ravimiamet

sia elvim - latanoprost - silmatilgad, lahus - 50mcg 1ml 2.5ml 1tk

Estonia - estone - Ravimiamet

sandoz pharmaceuticals d.d. - mükofenoolhape - õhukese polümeerikattega tablett - 500mg 120tk; 500mg 250tk; 500mg 180tk; 500mg 50tk; 500mg 150tk; 500mg 100tk